Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Geneva | OTHER |
Not provided
Not provided
Not provided
The behavioral and psychological symptoms of dementia affect up to 80% of long-term facilities residents with severe dementia. They seriously alter the quality of life of patients, relatives, and health professionals. Management involves correcting somatic and psychiatric factors and implementing non-drug interventions. Nevertheless, often drug treatments must be introduced with the limitations related to their effectiveness and adverse effects.
The investigators hypothesize that medical cannabinoids will improve neuropsychiatric and behavioral symptoms of patients with severe dementia.
The investigators assessed the feasibility and safety of administering a cannabis oil that contains tetrahydrocannabinol (THC) and Cannabidiol (CBD) during an initial study of about two years, observing an overall improvement, excellent tolerance to the treatment, and the possibility of reducing or even stopping other drugs.
This research project aims to study the efficacy of medical cannabis oil in improving the quality of life of dementia patients experimenting with behavioral and psychological symptoms.
The study design is a placebo-controlled cross-over trial. The patients, the relatives, the health care professionals, and the study staff will be blinded.
Medical cannabis treatment is a cannabis oil that contains THC and CBD in a 1:2 ratio. The initial dose of 7 drops (2.5 mg THC and 5 mg CBD) will be gradually augmented and adjusted individually to a maximum of 56 drops (20 mg THC and 40 mg CBD) per day, divided into two administrations. Placebo is an edible oil with the same color, smell, and flavor as medical cannabis oil given with the same dosage scheme.
Patients will take medical cannabis oil for 8 weeks, in addition to their usual treatments.
The study is divided into two 8-week periods. Participants will be randomized 1:1 between cannabinoids/placebo and placebo/ cannabinoids sequences and will receive the cannabis oil during one of these periods and the placebo during the other.
Participants will observe a wash-out week between the two study periods, and a final observation week without treatment intake is planned at the end of the second period.
Rating scales to evaluate the efficacy will be assessed before treatment, after 28 days, at the end of periods, and at the end of the study. Blood pressure will be evaluated daily. Vital signs, blood formula, and the reduction or discontinuation of other drugs will be recorded periodically. In addition, the health professionals' and relatives' appraisals will be recorded at five-time points.
A blood test at the beginning and the end of each period will allow the evaluation of the potential drug-drug interactions and the pharmacokinetics of cannabinoids. The cytochromes P450 (1A2, 2B6, 2C9, 2C19, 2D6, 3A4/5) enzymatic activity will be evaluated by phenotyping after Geneva micro-cocktail intake. The therapeutic drug monitoring will be measured at a steady-state characterizing the plasma through levels of THC, its two metabolites, 11-hydroxy-tetrahydrocannabinol and free carboxy-tetrahydrocannabinol, and CBD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cannabis Sativa Oil first, then Placebo | Experimental | This arm will start with the active comparator for the first period and change to the placebo in the second period |
|
| Placebo first, then Cannabis Sativa Oil | Experimental | This arm will start with the placebo for the first period and change to the active comparator in the second period |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cannabis Sativa Oil | Drug | Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cohen-Mansfield Agitation Inventory Scale (CMAI) | Change from baseline in the Cohen-Mansfield Agitation Inventory score. Scores range from 29 to 203 - higher scores mean a worse outcome ( A total score >45 is usually regarded as clinically significant agitation). | 4 and 8 weeks - after 1 week washout |
| Measure | Description | Time Frame |
|---|---|---|
| Neuropsychiatric Inventory (NPI) | Change from baseline in the Neuropsychiatric Inventory score. Scores range from 0 to 144 - higher scores mean a worse outcome. | 4 and 8 weeks - after 1 week wash-out |
| Unified Parkinson disease rigidity scale (UPDRS) |
| Measure | Description | Time Frame |
|---|---|---|
| Blood Count 1 | Red Blood Cells, White blood cells, Platelets x1000/mm3 | 8 weeks |
| Blood Count 2 | Haemoglobin g/dL | 8 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sophie Pautex, Prof. | HUG | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| FAHPA | Geneva | Canton of Geneva | 1206 | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37293434 | Derived | Bianchi F, Pautex S, Wampfler J, Curtin F, Daali Y, Desmeules JA, Broers B. Medical cannabinoids for painful symptoms in patients with severe dementia: a randomized, double-blind cross-over placebo-controlled trial protocol. Front Pain Res (Lausanne). 2023 May 24;4:1108832. doi: 10.3389/fpain.2023.1108832. eCollection 2023. |
| Label | URL |
|---|---|
| Study Protocol | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Hemp virgin seed oil |
|
Change from baseline in the Unified Parkinson disease rating scale (UPDRS - item 22) rigidity score. Scores range from 0 to 4 - higher scores mean a worse outcome.
| 4 and 8 weeks - after 1 week wash-out |
| Pain (Doloplus) | Change from baseline in the Doloplus score. Scores range from 0 to 30 - higher scores mean a worse outcome. | 4 and 8 weeks - after 1 week wash-out |
| Daily activity | Change from baseline in the score evaluating the most incapacitating daily activity. Scores range 0 to 10 - higher scores mean a greater difficulty for patients. | 4 and 8 weeks - after 1 week wash-out |
| Behavioral Trouble | Change from baseline in the score evaluating the most incapacitating behavioral trouble. Scores range 0 to 10 - higher scores mean a greater trouble. | 4 and 8 weeks - after 1 week wash-out |
| Team | Score evaluating the team's impression of change. Scores range 1 to 7. Higher scores mean greater deterioration. | 4 and 8 weeks - after 1 week wash-out |
| Family | Score evaluating the family's impression of change. Scores range 1 to 7. Higher scores mean greater deterioration. | 4 and 8 weeks - after 1 week wash-out |
| Evolution of dosages for each patient | Dosage adjustments of medical cannabis and psychotropic drugs. | 4 and 8 weeks |
| Change in enzymatic activity | Change in cytochromes P450 (1A2, 2B6, 2C9, 2C19,2D6 and 3A4/5 ) enzymatic activities using Geneva cocktail approach. | 8 weeks |
| Therapeutic Drug Monitoring | Therapeutic drug monitoring of plasma concentrations of Tetrahydrocannabinol, 11-Hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, Cannabidiol. | 8 weeks |
| Endocannabinoids | Evaluation of plasma levels of endocannabinoids - anandamide and 2-arachidonylglycerol. | 8 weeks |
| Blood Count 3 | Hematocrit % | 8 weeks |
| Blood Count 4 | Neutrophiles,Lymphocytes, Monocytes, Eosinophils and Basophils % | 8 weeks |
| Blood pressure | Blood pressure measurements - systolic and diastolic mmHG. | through study completion, an average of 5 months |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001526 | Behavioral Symptoms |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| C587251 | nabiximols |
Not provided
Not provided
Not provided